<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03311087</url>
  </required_header>
  <id_info>
    <org_study_id>HLM_JDR6</org_study_id>
    <nct_id>NCT03311087</nct_id>
  </id_info>
  <brief_title>Conduct of Nasal High Flow Oxygen in Acute Respiratory Failure</brief_title>
  <official_title>Conduct of High Flow Nasal Cannula Oxygen During Acute Hypoxemic Respiratory Failure: a Multicentre Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Louis Mourier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Louis Mourier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although many studies have investigated the clinical benefits of nasal high flow during acute
      hypoxemic respiratory failure, there is no data (and even less so recommendations) on how to
      best conduct this technique, including its initiation and its weaning periods. Investigators
      will assess in a multicenter, observational study, the way clinicians use nasal high flow
      therapy in patients with acute respiratory failure in order to try identify one or more
      strategies that may be then compared in an interventional study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nasal high flow oxygen therapy is increasingly used as a first-line treatment for hypoxemic
      acute respiratory failure, because of its remarkable tolerance (in comparison with NIV) and
      its physiological effects (nasopharyngeal dead space washout, positive end-expiratory
      pressure effect with possible alveolar recruitment, better matching with the patient's
      inspiratory flow, more reliable and adjustable FiO2); that together contribute to a reduction
      in respiratory workload and better oxygenation.

      Although many studies have investigated the clinical benefits of nasal high flow during acute
      hypoxemic respiratory failure, there are no data (and even less recommendations) on how to
      best conduct this technique, including its initiation and its weaning periods.

      Because different approaches exist among clinicians, investigators believe that a multicenter
      observational study that would collect data regarding the different ways high flow is
      conducted in patients with acute respiratory failure is necessary before performing an
      interventional study that would test and compare different strategies in order to answer the
      question: what are the best strategies (in terms of flow and FiO2 settings) to initiate and
      to wean high-flow oxygen therapy in patients with acute respiratory failure?

      Investigators will assess in a multicenter, observational study, the way clinicians use nasal
      high flow therapy in patients with acute respiratory failure in order to try identify one or
      more strategies that may be then compared in an interventional study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>values of gas flow over time (in liters per minute)</measure>
    <time_frame>entire duration of high flow therapy (5 to 7 days)</time_frame>
    <description>values of gas flow set on the device of nasal high flow will be monitored over time so as to describe how physicians set and modify this parameter during treatment with nasal high flow</description>
  </primary_outcome>
  <primary_outcome>
    <measure>values of fraction in inspired oxygen (FiO2) over time (between 0.21 and 1.0)</measure>
    <time_frame>entire duration of high flow therapy (5 to 7 days)</time_frame>
    <description>values of FiO2 set on the device of nasal high flow will be monitored over time so as to describe how physicians set and modify this parameter during treatment with nasal high flow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>respiratory rate (breath per minute)</measure>
    <time_frame>entire duration of high flow therapy (5 to 7 days)</time_frame>
    <description>values of respiratory rate upon initiation of nasal high flow and at each change of nasal high flow parameters (gas flow or FiO2) will be monitored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse oximetry (SpO2) (percentage)</measure>
    <time_frame>entire duration of high flow therapy (5 to 7 days)</time_frame>
    <description>values of oxgen saturation upon initiation of nasal high flow and at each change of nasal high flow parameters (gas flow or FiO2) will be monitored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>values of the Respiratory rate Oxygenation indeX (&quot;ROX&quot;) index defined as the ratio of pulse oximetry over fraction of inspired oxygen to respiratory rate</measure>
    <time_frame>12 hours</time_frame>
    <description>values of the &quot;ROX&quot; index will be monitored at different time points (2, 6 and 12 hours after nasal high flow therapy initiation)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Respiratory Failure With Hypoxia</condition>
  <condition>Hypoxemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients admitted to an ICU or an intermediate care unit, who require nasal high flow
        oxygen therapy for acute hypoxemic respiratory failure
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 or older

          -  admitted to the intensive care unit (ICU) or to the intermediate care for acute
             hypoxemic respiratory failure (whatever the cause)

          -  treated with nasal high flow oxygen therapy

          -  with a minimal FiO2 of FiO2≥50% and a gas flow ≥40 L/min

          -  anticipated duration of nasal high flow therapy greater or equal to 24 hours

        Non-inclusion Criteria:

          -  prophylactic, post-extubation nasal high flow therapy

          -  palliative nasal high flow therapy (do-not-resuscitate order)

        Exclusion criteria

        - nasal high flow therapy administered for less than 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Damien Ricard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Damien Ricard, MD, PhD</last_name>
    <phone>+33147606195</phone>
    <email>jean-damien.ricard@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Messika, MD, PhD</last_name>
    <phone>+33147606195</phone>
    <email>jonathan.messika@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Réanimation Médico-Chirurgicale</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Damien Ricard, MD, PhD</last_name>
      <email>jean-damien.ricard@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Guillaume Berquier, MD</last_name>
      <email>gberquier@yahoo.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation Médicale</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre Quenot, MD</last_name>
      <email>jean-pierre.quenot@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation Médicale</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Terzi, MD, PhD</last_name>
      <email>nterzi@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation</name>
      <address>
        <city>Longjumeau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthieu Le Meur, MD</last_name>
      <email>m.lemeur@gh-nord-essonne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation Chirurgicale</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Eric Danin, MD</last_name>
      <email>danin.pe@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Runge, MD</last_name>
      <email>Isabelle.runge@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation Médicale et Resiratoire</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elise Morawiec, MD</last_name>
      <email>elisemorawiec@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>maxens Decavèle, MD</last_name>
      <email>maxencesar@hotmail.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation Médicale</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ania nieszkowska, MD</last_name>
      <email>ania.nieszkowska@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre Frat, MD</last_name>
      <email>Jean-Pierre.FRAT@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation Médicale</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Girault, MD</last_name>
      <email>Christophe.Girault@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation Médicale</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>stephan Hermann, MD, PhD</last_name>
      <email>stephanehrmann@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Chevalier S, Herbland A, Fartoukh M, Constantin JM, Tonnelier JM, Pierrot M, Mathonnet A, Béduneau G, Delétage-Métreau C, Richard JC, Brochard L, Robert R; FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015 Jun 4;372(23):2185-96. doi: 10.1056/NEJMoa1503326. Epub 2015 May 17.</citation>
    <PMID>25981908</PMID>
  </reference>
  <reference>
    <citation>Sztrymf B, Messika J, Bertrand F, Hurel D, Leon R, Dreyfuss D, Ricard JD. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med. 2011 Nov;37(11):1780-6. doi: 10.1007/s00134-011-2354-6. Epub 2011 Sep 27.</citation>
    <PMID>21946925</PMID>
  </reference>
  <reference>
    <citation>Sztrymf B, Messika J, Mayot T, Lenglet H, Dreyfuss D, Ricard JD. Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study. J Crit Care. 2012 Jun;27(3):324.e9-13. doi: 10.1016/j.jcrc.2011.07.075. Epub 2011 Sep 29.</citation>
    <PMID>21958974</PMID>
  </reference>
  <reference>
    <citation>Messika J, Ben Ahmed K, Gaudry S, Miguel-Montanes R, Rafat C, Sztrymf B, Dreyfuss D, Ricard JD. Use of High-Flow Nasal Cannula Oxygen Therapy in Subjects With ARDS: A 1-Year Observational Study. Respir Care. 2015 Feb;60(2):162-9. doi: 10.4187/respcare.03423. Epub 2014 Nov 4.</citation>
    <PMID>25371400</PMID>
  </reference>
  <reference>
    <citation>Roca O, Messika J, Caralt B, García-de-Acilu M, Sztrymf B, Ricard JD, Masclans JR. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. J Crit Care. 2016 Oct;35:200-5. doi: 10.1016/j.jcrc.2016.05.022. Epub 2016 May 31.</citation>
    <PMID>27481760</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Louis Mourier</investigator_affiliation>
    <investigator_full_name>Prof Jean-Damien RICARD</investigator_full_name>
    <investigator_title>Professor of Intensive Care Medicine</investigator_title>
  </responsible_party>
  <keyword>high flow nasal oxygen</keyword>
  <keyword>acute hypoxemic respiratory failure</keyword>
  <keyword>adults</keyword>
  <keyword>intensive care unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

